Cardiac Radioablation for VT

Launched by WILLIAM BEAUMONT HOSPITALS · Sep 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called cardiac radioablation for patients with refractory ventricular tachycardia (VT), which is a fast and abnormal heart rhythm that can be dangerous. The goal is to find out the lowest dose of radiation needed to effectively treat VT and to use advanced imaging called Delayed Enhancement Cardiac MRI to better identify the areas in the heart that need treatment.

To be eligible for the trial, participants must be at least 18 years old and have an automatic implanted cardiac defibrillator (AICD) to help manage their heart rhythm. They should have experienced at least two episodes of VT within the last eight weeks and have had previous treatments for VT that didn’t work. Participants will receive targeted radiation treatment, and it’s important that they are likely to live for at least another year without VT. Women of childbearing age must ensure they are not pregnant or breastfeeding during the study. Overall, this trial aims to improve treatment options for patients struggling with challenging heart rhythms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must be 18 years or older.
• • Automatic implanted cardiac defibrillator present.
• • VT is monomorphic with at least two episodes of VT within an eight week (56 day) period as recorded by an AICD or heart failure related to VT or VT storm.
• • Ejection fraction ≥20%.
• • At least one previous cardiac ablation for VT.
• • VT refractory despite antiarrhythmic medications.
• • Likely to live for 12 months in the absence of VT.
• • AICD in a position in the chest RT to be given without direct radiation.
• • Woman of reproductive age must ensure that she won't become pregnant or breastfeed at the time of RT.
• • The participant has no contraindications to a Cardiac MRI as per routine Cardiology practice.
• Exclusion Criteria:
• • Class IV heart failure
• • Abandoned leads.
• • Prior radiation therapy to the chest or upper abdomen.
• • Interstitial lung disease.